- Conditions
- Pancreatic Cancer, Head and Neck Cancer, Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Corewell Health East
- Other
- Eligibility
- Not listed
- Enrollment
- 3,028 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 2,380
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Cholangiocarcinoma, Cholangiocarcinoma, Pancreatic Cancer, Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer, Unresectable Cholangiocarcinoma
- Interventions
- Entinostat, Nivolumab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Solid Tumors, Pancreatic Cancer
- Interventions
- itacitinib, Gemcitabine, nab-paclitaxel, filgrastim
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 5 more
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- Regorafenib, Gemcitabine Hydrochloride
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Binimetinib, Encorafenib
- Drug
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Los Angeles, California • Baltimore, Maryland + 2 more
- Conditions
- GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
- Interventions
- RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
- Drug
- Lead sponsor
- RayzeBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Duarte, California • Irvine, California + 27 more
- Conditions
- Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
- Interventions
- bortezomib, gemcitabine hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Solid Tumors
- Interventions
- BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig, Pemetrexed, Carboplatin, Nab-paclitaxel, Gemcitabine, Paclitaxel
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 16
- States / cities
- San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 10 more
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
- Interventions
- Specimen sample
- Diagnostic Test
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Pancreas Cancer
- Interventions
- Biofeedback, Active Breathing Control Technique
- Behavioral
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Biliary Disease, Pancreatitis, Gastrointestinal Neoplasms
- Interventions
- clinical course
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- Not listed
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, DDX5 Degrader FL118, Magnetic Resonance Imaging
- Procedure · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Temsirolimus, Gemcitabine
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
- Interventions
- ASP546C
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Miami, Florida + 15 more
- Conditions
- Pancreatic Cancer
- Interventions
- MVT-5873, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel
- Drug
- Lead sponsor
- BioNTech Research & Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Sarasota, Florida + 2 more
- Conditions
- Stage III Pancreatic Cancer
- Interventions
- SOC, NanoKnife System
- Drug · Device
- Lead sponsor
- Angiodynamics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 14
- States / cities
- La Jolla, California • Gainesville, Florida • Miami, Florida + 10 more
- Conditions
- Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell), Pancreas Cancer, Duct Cell Adenocarcinoma
- Interventions
- ADC
- Drug
- Lead sponsor
- MBrace Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 7
- States / cities
- San Francisco, California • Grand Rapids, Michigan • East Brunswick, New Jersey + 4 more
- Conditions
- Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
- Interventions
- mFOLFIRINOX, Algenpantucel-L Immunotherapy, SBRT, Gemcitabine
- Drug · Biological · Radiation
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Louisville, Kentucky • Burlington, Massachusetts • Albuquerque, New Mexico + 1 more
- Conditions
- VHL Pancreatic Neuroendocrine Tumors, Von Hippel-Lindau Disease, Neuroendocrine Tumors
- Interventions
- 68-Gallium DOTATATE
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 740 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2036
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chemotherapy-induced Thrombocytopenia
- Interventions
- Romiplostim, Placebo
- Biological · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 22
- States / cities
- Jonesboro, Arkansas • Anaheim, California • Orange, California + 18 more
- Conditions
- Melanoma, Breast Cancer, Head and Neck Squamous Cell Cancer, Liver Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma
- Interventions
- Vaccinia virus (vvDD-CDSR)
- Biological
- Lead sponsor
- David Bartlett
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Pancreatic Cancer
- Interventions
- MeIQx, Pancreatectomy
- Radiation · Procedure
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Pancreatic Cancer
- Interventions
- Canakinumab, Tislelizumab, Nab-Paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- New York, New York
- Conditions
- Head and Neck Cancer, Pancreatic Cancer, Cancer Pancreas
- Interventions
- [Ga-68]MTP220 PET/CT Scan
- Drug
- Lead sponsor
- Qiubai Li
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio